Cellectis S.A. (NASDAQ:CLLS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.3333.

A number of research firms recently weighed in on CLLS. Clear Str upgraded Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Finally, Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price objective on the stock.

Cellectis Stock Down 2.3%

CLLS opened at $3.36 on Wednesday. Cellectis has a 1-year low of $1.17 and a 1-year high of $5.48. The stock’s fifty day simple moving average is $3.62 and its 200 day simple moving average is $3.97. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 0.98. The stock has a market cap of $337.14 million, a PE ratio of -5.01 and a beta of 2.91.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%. The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $10.74 million. As a group, research analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

A number of institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new stake in shares of Cellectis in the fourth quarter valued at about $34,000. Millennium Management LLC boosted its position in shares of Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the period. Delaney Dennis R bought a new stake in shares of Cellectis in the third quarter valued at about $68,000. B Group Inc. boosted its position in shares of Cellectis by 0.8% in the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after acquiring an additional 25,000 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Cellectis in the third quarter valued at about $72,000. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.